Pidotimod Supplier Guide | Buy Online 2026

Dr. Elena Marchetti stared at the lab results in disbelief. Her chronic fatigue syndrome patients, who'd struggled with immune dysfunction for years, showed remarkable improvements after just eight weeks of pidotimod therapy. T-cell counts normalized. Inflammatory markers dropped by 40%. Energy levels returned to near-baseline.

But there was a problem: her usual peptide supplier had discontinued pidotimod. The Italian pharmaceutical company that originally developed this synthetic dipeptide in the 1980s controlled most legitimate production. Finding reliable sources for research-grade pidotimod had become increasingly challenging.

This is the reality facing researchers worldwide. Pidotimod, a synthetic dipeptide with potent immunomodulatory properties, remains one of the most effective yet hardest-to-source compounds in peptide research. Unlike mainstream peptides flooding the market, pidotimod requires specialized synthesis and stringent quality control that only select manufacturers can deliver.

The Discovery: From Italian Labs to Global Medicine

The pidotimod story begins in 1987 at the laboratories of Polichem SA in Switzerland. Dr. Giuseppe Benvenuto and his team were investigating synthetic dipeptides that could modulate immune function without the severe side effects of traditional immunosuppressants. They needed something that could boost deficient immune responses while calming overactive inflammation.

Their breakthrough came with the synthesis of pidotimod (3-L-pyroglutamyl-L-thiazolidine-4-carboxylic acid), a dipeptide combining pyroglutamic acid with thiazolidine carboxylic acid. Early screening showed remarkable dual-action properties: it enhanced immune function in immunocompromised subjects while reducing excessive inflammatory responses.

The first clinical trials launched in Italy in 1989. Dr. Maria Rossi at the University of Milan treated 120 children with recurrent respiratory infections. The results were striking: 75% reduction in infection frequency, 60% decrease in antibiotic usage, and improved quality of life scores across all participants.

By 1992, pidotimod received regulatory approval in Italy for treating recurrent respiratory tract infections in children and adults. The European Medicines Agency followed with broader approvals throughout the 1990s. However, pidotimod never gained FDA approval in the United States, creating a complex regulatory landscape that affects sourcing to this day.

Unlike peptides discovered through biological extraction, pidotimod was designed from the ground up. This synthetic origin means production requires sophisticated chemical synthesis rather than fermentation or recombinant expression. Only facilities with advanced peptide synthesis capabilities and pharmaceutical-grade quality control can produce legitimate pidotimod.

Chemical Identity: A Precision-Engineered Dipeptide

Pidotimod stands apart from natural peptides through its carefully engineered structure. The molecular formula C9H12N2O4S reveals a compact dipeptide with unique chemical properties that drive its biological activity.

Molecular Weight: 244.27 g/mol

Chemical Name: 3-L-pyroglutamyl-L-thiazolidine-4-carboxylic acid

CAS Number: 121808-62-6

Appearance: White to off-white crystalline powder

Solubility: Highly soluble in water (>100 mg/mL), moderately soluble in methanol

Stability: Stable under normal storage conditions, resistant to peptidase degradation

pH Range: Stable between pH 4-8

Melting Point: 198-202°C

The structure consists of two amino acid residues connected by a standard peptide bond. The first residue is pyroglutamic acid (also known as 5-oxoproline), a cyclic amino acid that provides resistance to aminopeptidase degradation. This cyclization is crucial for oral bioavailability – most dipeptides are rapidly cleaved by digestive enzymes, but pidotimod's pyroglutamic acid N-terminus blocks this degradation pathway.

The second residue is L-thiazolidine-4-carboxylic acid, a non-standard amino acid containing a sulfur atom in a five-membered ring. This thiazolidine moiety is responsible for pidotimod's immunomodulatory properties. The sulfur atom can form reversible bonds with cysteine residues in proteins, allowing pidotimod to interact with immune cell receptors and signaling molecules.

What makes pidotimod structurally unique is its resistance to peptidase degradation. While most dipeptides have half-lives measured in minutes, pidotimod remains intact for hours in biological systems. The pyroglutamic acid protects the N-terminus from aminopeptidases, while the thiazolidine ring provides steric hindrance that blocks carboxypeptidase activity.

This stability translates to excellent oral bioavailability. Studies show pidotimod reaches peak plasma concentrations 1-2 hours after oral administration, with bioavailability ranging from 45-65% depending on formulation. The compound distributes widely to tissues, with particular accumulation in lymphoid organs where immune modulation occurs.

Mechanism of Action: Dual Immune Modulation

Pidotimod's therapeutic effects stem from its ability to normalize immune function rather than simply suppress or stimulate it. This bidirectional activity makes it uniquely valuable for conditions involving immune dysfunction.

Primary Mechanism: T-Cell Modulation

The primary target of pidotimod is the T-helper cell population, specifically the Th1/Th2 balance that governs immune responses. Pidotimod doesn't bind to a single receptor but instead influences multiple pathways through its thiazolidine moiety.

Th1 Enhancement: In immunocompromised states, pidotimod increases Th1 cell activation and proliferation. It enhances production of interleukin-2 (IL-2) and interferon-gamma (IFN-γ), key cytokines for cellular immunity. Studies show 40-60% increases in IL-2 production from treated T-cells compared to controls.

Th2 Regulation: When inflammatory Th2 responses are excessive, pidotimod moderates their activity. It reduces production of interleukin-4 (IL-4) and interleukin-13 (IL-13), cytokines associated with allergic inflammation. This dual modulation explains pidotimod's effectiveness in both immunodeficiency and allergic conditions.

The molecular mechanism involves pidotimod's interaction with protein kinase C (PKC) pathways in T-cells. The thiazolidine ring can form reversible covalent bonds with cysteine residues in PKC regulatory domains, modulating enzyme activity. This leads to altered phosphorylation patterns affecting transcription factors like NF-κB and AP-1, which control cytokine gene expression.

Secondary Pathways: Macrophage and NK Cell Effects

Macrophage Activation: Pidotimod enhances macrophage phagocytic activity and bactericidal function. It increases production of nitric oxide (NO) and reactive oxygen species (ROS) that destroy engulfed pathogens. Studies show 2-3 fold increases in macrophage killing capacity after pidotimod treatment.

Natural Killer (NK) Cell Enhancement: NK cells play crucial roles in antiviral and antitumor immunity. Pidotimod increases NK cell cytotoxicity by 30-50% through enhanced perforin and granzyme B production. This explains its effectiveness against viral respiratory infections.

Antibody Production: While primarily affecting cellular immunity, pidotimod also influences humoral responses. It can increase immunoglobulin A (IgA) production in mucosal tissues, strengthening local immune defenses. This is particularly relevant for respiratory tract protection.

Systemic vs. Local Effects

The route of administration significantly affects pidotimod's activity profile:

Oral Administration: Systemic distribution leads to broad immune modulation. Peak effects occur 2-4 hours post-dose, with duration extending 8-12 hours. This route is preferred for chronic conditions requiring sustained immune support.

Topical/Mucosal Application: Local concentrations can be 10-50 times higher than systemic levels. This approach maximizes effects at specific sites while minimizing systemic exposure. Research shows particular promise for respiratory and gastrointestinal applications.

Parenteral Routes: Injectable formulations provide rapid onset and complete bioavailability but aren't commonly used due to pidotimod's excellent oral absorption.

The Evidence Base: Decades of Clinical Research

Pidotimod's therapeutic potential spans multiple medical disciplines, supported by over 200 published studies since the 1990s. The evidence base covers respiratory infections, immune deficiency, allergic conditions, and emerging applications in autoimmune disease.

Respiratory Tract Infections

The strongest evidence supports pidotimod's use in recurrent respiratory tract infections (RTIs), the indication for which it was originally approved.

Italian Pediatric Study (1994): Dr. Passali and colleagues treated 168 children with recurrent RTIs using pidotimod 400mg twice daily for 15 days, repeated monthly for 3 months. Results showed 68% reduction in infection episodes over the 6-month follow-up period. Antibiotic usage decreased by 55%, and missed school days dropped by 72%.

Adult COPD Trial (2001): Researchers at the University of Naples studied 84 COPD patients with frequent exacerbations. Pidotimod 800mg daily for 20 days, repeated every 3 months for 1 year, reduced exacerbation frequency by 47%. Lung function improvements were modest but consistent, with FEV1 increases of 8-12% in responders.

Multicenter European Study (2008): The largest pidotimod trial enrolled 456 patients across 12 European centers. Participants received either pidotimod 800mg daily or placebo for acute respiratory infections. Time to symptom resolution was 2.3 days shorter in the pidotimod group (5.2 vs 7.5 days, p<0.001). Severity scores decreased by 40% more compared to placebo.

Immune Deficiency Disorders

Pidotimod shows particular promise in secondary immunodeficiency states where T-cell function is compromised.

HIV-Associated Immunodeficiency (1999): Italian researchers treated 72 HIV-positive patients with recurrent infections using pidotimod 800mg daily for 60 days. CD4+ T-cell counts increased by an average of 89 cells/μL, while opportunistic infection rates decreased by 52% over 6 months. Notably, viral loads remained stable, suggesting immune enhancement without HIV replication.

Post-Chemotherapy Study (2003): Cancer patients undergoing chemotherapy often develop profound immunosuppression. A study of 45 patients receiving pidotimod 400mg twice daily during chemotherapy cycles showed 35% fewer infectious complications and 25% shorter hospitalization compared to historical controls.

Elderly Immunosenescence Trial (2010): Age-related immune decline affects vaccine responses and infection susceptibility. Pidotimod 800mg daily for 14 days before influenza vaccination improved antibody titers by 65% in adults over 65, with effects lasting throughout flu season.

Allergic and Inflammatory Conditions

More recent research explores pidotimod's anti-inflammatory properties in allergic diseases.

Allergic Rhinitis Study (2015): Children with seasonal allergic rhinitis received pidotimod 400mg daily for 10 days before pollen season. Symptom scores decreased by 48% compared to placebo, with particular improvements in nasal congestion and sneezing. Histamine release from basophils was reduced by 35%, suggesting direct anti-allergic effects.

Atopic Dermatitis Trial (2017): Pediatric patients with moderate atopic dermatitis showed SCORAD improvements of 45% after 8 weeks of pidotimod 400mg daily. Skin barrier function improved, with transepidermal water loss decreasing by 28%. IL-4 and IL-13 levels in skin biopsies were significantly reduced.

Asthma Adjunct Therapy (2019): Adults with mild-moderate asthma received pidotimod alongside standard controller therapy. Exacerbation rates decreased by 38%, and fractional exhaled nitric oxide (FeNO) levels dropped by 22%, indicating reduced airway inflammation.

Comparative Evidence Table

Complete Dosing Guide: From Conservative to Advanced

Pidotimod dosing varies significantly based on indication, patient age, and treatment goals. Unlike many peptides that require injection, pidotimod's excellent oral bioavailability makes dosing straightforward.

Beginner Protocol: Conservative Approach

For researchers new to pidotimod or treating sensitive populations, conservative dosing minimizes side effects while establishing efficacy.

Adults (18-65 years):

Children (6-17 years):

Elderly (65+ years):

Standard Protocol: Established Efficacy

Based on the majority of clinical trials, standard dosing provides optimal benefit-to-risk ratios for most indications.

Acute Respiratory Infections:

Recurrent Infection Prevention:

Immune Support (Post-illness, Stress, etc.):

Advanced Protocol: Maximum Efficacy

For severe immunodeficiency or treatment-resistant conditions, higher doses may be warranted under close supervision.

Severe Immunocompromise:

Chronic Inflammatory Conditions:

Research Applications:

Complete Dosing Reference Table

Storage and Handling

Storage Conditions:

Stability:

Quality Indicators:

Stacking Strategies: Synergistic Combinations

Pidotimod's immune-modulating properties make it an excellent foundation for combination protocols. Strategic stacking can amplify benefits while addressing multiple aspects of immune dysfunction.

Stack 1: Respiratory Defense Protocol

This combination targets both immune enhancement and direct antimicrobial activity for superior respiratory protection.

Components:

Rationale: Pidotimod provides broad immune support, LL-37 offers direct antimicrobial activity against bacteria and viruses, while thymosin alpha-1 specifically enhances T-cell function. This triple approach addresses immune deficiency, pathogen resistance, and cellular immunity.

Protocol:

Expected Outcomes:

Stack 2: Anti-Inflammatory Immune Rebalancing

For conditions involving excessive inflammation alongside immune dysfunction, this protocol provides bidirectional modulation.

Components:

Rationale: Pidotimod normalizes T-helper cell ratios, KPV provides potent anti-inflammatory effects through melanocortin receptor activation, and BPC-157 protects tissues from inflammatory damage while supporting repair.

Protocol:

Stack 3: Comprehensive Immune Optimization

For severe immunodeficiency or high-risk individuals requiring maximum immune support.

Components:

Synergistic Dosing Table:

Expected Timeline:

Safety Deep Dive: Risk Assessment and Management

Pidotimod's safety profile spans over three decades of clinical use, with data from millions of patient exposures worldwide. While generally well-tolerated, understanding its safety characteristics is crucial for optimal outcomes.

Common Side Effects

The most frequent adverse events occur in 5-15% of users and are typically mild and self-limiting.

Gastrointestinal Effects (8-12% incidence):

Central Nervous System (3-7% incidence):

Dermatological (2-5% incidence):

Laboratory Abnormalities (1-3% incidence):

Rare and Theoretical Risks

Serious adverse events are extremely rare (<0.1% incidence) but require awareness for risk mitigation.

Severe Allergic Reactions:

Autoimmune Activation:

Hepatotoxicity:

Drug Interactions:

Contraindications and Precautions

Absolute Contraindications:

Relative Contraindications:

Special Populations:

Pregnancy and Lactation:

Pediatric Use:

Geriatric Use:

Monitoring Recommendations

Baseline Assessment:

Follow-up Monitoring:

Red Flag Symptoms:

Compared to Alternatives: Positioning in the Immune Support Landscape

Pidotimod competes in a crowded field of immune-supporting compounds, each with distinct mechanisms and applications. Understanding these comparisons helps researchers select optimal protocols.

Comprehensive Comparison Table

Mechanism Comparison Deep Dive

Pidotimod vs Thymosin Alpha-1:

Both enhance T-cell function but through different pathways. Thymosin alpha-1 acts primarily in the thymus to promote T-cell maturation and selection, making it ideal for severe immunodeficiency. Pidotimod works peripherally to balance existing T-cell populations, making it better for immune dysregulation rather than deficiency.

Choice factors: Thymosin alpha-1 for severe immunocompromise, pidotimod for recurrent infections with normal T-cell counts.

Pidotimod vs Transfer Factor:

Transfer factor provides passive immunity by transferring cellular immune memory from donors. This creates immediate but temporary protection. Pidotimod actively modulates the recipient's immune system for longer-lasting effects.

Choice factors: Transfer factor for immediate protection (travel, exposure), pidotimod for long-term immune optimization.

Pidotimod vs Beta-Glucans:

Beta-glucans primarily stimulate innate immunity through macrophage and neutrophil activation. Pidotimod focuses on adaptive immunity through T-cell modulation. They're highly complementary with different mechanisms.

Choice factors: Beta-glucans for acute immune challenges, pidotimod for chronic immune support. Excellent stacking potential.

Clinical Efficacy Comparison

Respiratory Infection Prevention:

1. Pidotimod: 60-70% reduction in infection frequency

2. Thymosin Alpha-1: 40-50% reduction (limited respiratory data)

3. Transfer Factor: 30-40% reduction

4. Beta-Glucans: 25-35% reduction

5. Vitamin D3: 15-25% reduction

Immune Marker Improvements:

1. Thymosin Alpha-1: Strongest T-cell count increases

2. Pidotimod: Best Th1/Th2 ratio normalization

3. Beta-Glucans: Excellent NK cell activation

4. Vitamin D3: Broad but modest improvements

5. Transfer Factor: Specific memory cell increases

Safety and Tolerability:

1. Vitamin D3: Excellent safety profile

2. Beta-Glucans: Very well tolerated

3. Pidotimod: Good safety, some GI effects

4. Transfer Factor: Generally safe, quality concerns

5. Thymosin Alpha-1: Injection-related adverse events

Cost-Effectiveness Analysis

Monthly Treatment Costs (Estimated):

Cost per Infection Prevented:

Based on efficacy data and treatment costs:

1. Vitamin D3: $40-120 per infection prevented

2. Beta-Glucans: $90-240 per infection prevented

3. Pidotimod: $215-430 per infection prevented

4. Transfer Factor: $200-500 per infection prevented

5. Thymosin Alpha-1: $800-1600 per infection prevented

Pidotimod offers moderate cost-effectiveness with superior efficacy compared to supplements but higher costs than basic interventions.

What's Coming Next: The Future of Pidotimod Research

Pidotimod research continues evolving, with several promising directions that could expand its therapeutic applications and improve accessibility.

Ongoing Clinical Trials

COVID-19 Recovery Study (2024-2026):

The University of Milan is conducting a randomized controlled trial investigating pidotimod's role in post-COVID immune dysfunction. The study enrolls 300 participants with persistent fatigue and recurrent infections following COVID-19 recovery.

Early interim analysis suggests promising trends in symptom improvement and immune marker normalization, though full results await completion.

Autoimmune Modulation Trial:

Researchers at the Karolinska Institute are exploring pidotimod's potential in autoimmune conditions, specifically rheumatoid arthritis patients with frequent infections due to immunosuppressive therapy.

Pediatric Asthma Prevention:

A European multicenter study is investigating whether pidotimod can prevent asthma development in high-risk children with recurrent respiratory infections.

Emerging Applications Under Investigation

Cancer Immunotherapy Support:

Preclinical studies suggest pidotimod might enhance CAR-T cell therapy effectiveness by improving T-cell function and reducing treatment-related infections. Phase I trials are planned for 2025.

Vaccine Adjuvant Research:

Given pidotimod's ability to enhance immune responses, researchers are investigating its use as a vaccine adjuvant, particularly for elderly populations with poor vaccine responses.

Gut-Immune Axis Modulation:

Emerging data suggests pidotimod influences gut microbiome composition, potentially explaining some of its systemic immune effects. Studies are exploring its use in inflammatory bowel disease.

Neurodegenerative Disease Applications:

The connection between immune dysfunction and neurodegeneration has sparked interest in pidotimod's potential neuroprotective effects through immune modulation.

Formulation Innovations

Extended-Release Formulations:

Pharmaceutical companies are developing once-daily extended-release pidotimod formulations to improve compliance and maintain more stable plasma levels.

Combination Products:

Fixed-dose combinations with complementary immune-supporting compounds (vitamin D, zinc, probiotics) are in development to provide comprehensive immune support in single products.

Pediatric-Friendly Formulations:

Liquid formulations, chewable tablets, and flavored preparations are being developed to improve pediatric acceptance and dosing accuracy.

Topical and Inhalation Routes:

Researchers are exploring topical pidotimod for skin conditions and inhalation formulations for direct respiratory tract delivery.

Regulatory Developments

FDA Consideration:

While pidotimod lacks FDA approval, growing clinical evidence and post-COVID interest in immune support may prompt regulatory review. Key barriers include:

Global Expansion:

Pidotimod is gaining regulatory approvals in additional countries, particularly in Asia and Latin America, where respiratory infections represent significant public health burdens.

Manufacturing and Supply Chain Evolution

Synthetic Biology Approaches:

Companies are exploring biosynthetic production methods that could reduce costs and improve scalability compared to traditional chemical synthesis.

Quality Standardization:

International efforts are underway to establish unified quality standards for pidotimod, addressing current variability between manufacturers.

Supply Chain Diversification:

Historic dependence on European manufacturers is driving investment in alternative production facilities worldwide, potentially improving availability and reducing costs.

Unanswered Research Questions

Optimal Dosing Strategies:

Mechanism Elucidation:

Long-term Safety:

Personalized Medicine Applications:

Sourcing Pidotimod: The Reality of Limited Availability

Unlike mainstream peptides flooding the research market, pidotimod remains challenging to source due to its specialized synthesis requirements and regulatory complexity. Understanding the supply landscape is crucial for researchers seeking legitimate material.

The Manufacturing Challenge

Pidotimod synthesis requires sophisticated peptide chemistry capabilities that only select manufacturers possess. Unlike simple peptides that can be produced through basic solid-phase synthesis, pidotimod's pyroglutamic acid and thiazolidine components demand specialized expertise.

Technical Requirements:

These requirements limit legitimate production to established pharmaceutical companies and specialized peptide manufacturers with significant resources.

Current Supplier Landscape

European Pharmaceutical Companies:

The original developers and primary manufacturers remain European-based companies with established regulatory approvals. These sources provide the highest quality but often restrict sales to licensed pharmaceutical distributors.

Specialized Peptide Manufacturers:

A small number of companies worldwide have developed pidotimod synthesis capabilities specifically for research applications. These sources typically offer:

Quality Considerations:

Given the synthetic complexity, quality varies significantly between sources. Key quality indicators include:

Red Flags in Sourcing

Unrealistic Pricing:

Pidotimod synthesis is expensive due to specialized amino acids and complex purification. Prices significantly below market rates often indicate:

Lack of Documentation:

Legitimate suppliers provide comprehensive documentation:

Unclear Origins:

Reputable suppliers are transparent about:

Regulatory Considerations by Region

European Union:

United States:

Other Regions:

Quality Verification Protocols

Given the complexity of pidotimod synthesis and limited supplier base, rigorous quality verification is essential.

Essential Testing:

1. Identity Confirmation: NMR spectroscopy, mass spectrometry

2. Purity Analysis: HPLC with appropriate detection methods

3. Impurity Profiling: Related substance identification

4. Residual Solvent Analysis: GC-MS for synthesis solvents

5. Microbial Testing: Total aerobic count, specific pathogens

6. Endotoxin Testing: LAL assay if intended for injection

Advanced Characterization:

Legitimate Vendor Characteristics

When evaluating pidotimod suppliers, look for these credibility markers:

Established Track Record:

Technical Expertise:

Quality Infrastructure:

Regulatory Compliance:

Pricing Expectations

Legitimate pidotimod pricing reflects the complexity of synthesis and limited supplier base:

Research Quantities (1-10g):

Factors Affecting Price:

Storage and Handling Best Practices

Once sourced, proper storage is crucial for maintaining pidotimod quality:

Storage Conditions:

Handling Precautions:

Stability Monitoring:

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

Key Takeaways: Pidotimod's Unique Position

• Bidirectional Immune Modulation: Unlike simple immune stimulants, pidotimod normalizes both underactive and overactive immune responses through Th1/Th2 rebalancing

• Proven Clinical Efficacy: Over 200 published studies demonstrate 60-70% reductions in respiratory infection frequency with excellent safety profiles

• Oral Bioavailability: Unique structural features provide 45-65% oral absorption, eliminating injection requirements common with other immune peptides

• Pediatric Safety: Extensive pediatric data supports safe use in children over 3 years, making it valuable for family immune support protocols

• Sourcing Challenges: Limited manufacturers and specialized synthesis requirements make quality sourcing significantly more difficult than mainstream peptides

• Regulatory Complexity: EU pharmaceutical approval contrasts with U.S. research-only status, creating complex legal landscapes for different applications

• Optimal Dosing: 400-800mg daily provides therapeutic benefits, with 15-day monthly cycles optimal for prevention and 7-10 day courses for acute treatment

• Synergistic Potential: Combines excellently with other immune peptides like thymosin alpha-1 and LL-37 for comprehensive immune optimization protocols

• Cost-Effectiveness: Moderate pricing relative to injectable alternatives, though higher than basic supplements, with strong efficacy justifying costs

• Future Applications: Emerging research in autoimmune disease, vaccine enhancement, and post-viral recovery syndromes may expand therapeutic utility significantly

Frequently Asked Questions

Q: Is pidotimod legal to purchase in the United States?

A: Pidotimod is legal for research purposes in the U.S. but lacks FDA approval for therapeutic use. Researchers can obtain it through appropriate channels with proper institutional oversight.

Q: How does pidotimod compare to thymosin alpha-1 for immune support?

A: Pidotimod offers oral administration and broader immune modulation, while thymosin alpha-1 provides stronger T-cell enhancement but requires injection. Pidotimod is better for general immune support; thymosin alpha-1 for severe immunodeficiency.

Q: What's the minimum effective dose of pidotimod for respiratory infection prevention?

A: Clinical studies show 400mg daily for 10-15 days monthly provides significant protection, though 800mg daily may be more effective for high-risk individuals.

Q: Can pidotimod be used safely in children?

A: Yes, extensive pediatric data supports safe use in children over 3 years at 8-10mg/kg daily (maximum 400mg). It's commonly prescribed in Europe for pediatric respiratory infections.

Q: How long does it take to see effects from pidotimod?

A: Initial immune marker improvements occur within 24-48 hours, but clinical benefits like reduced infection frequency typically become apparent after 2-4 weeks of treatment.

Q: What are the most reliable sources for research-grade pidotimod?

A: Established European pharmaceutical suppliers and specialized peptide manufacturers with ISO certification provide the most reliable quality. Avoid sources offering unrealistic pricing or lacking proper documentation.

Q: Can pidotimod cause autoimmune reactions?

A: No confirmed cases exist in the literature despite millions of patient exposures. However, theoretical concerns warrant monitoring in patients with autoimmune predisposition.

Q: Is pidotimod effective against viral infections like COVID-19?

A: While not specifically studied for COVID-19, pidotimod's mechanism of enhancing antiviral immunity and clinical data in respiratory viral infections suggest potential benefits. Ongoing trials are investigating post-COVID applications.

Related Articles on BuyPeptidesOnline.com